Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study

Hau JT, Martin SJ, Roosa CA, Deshayes S, Hanke CW. Microporous Annealed Particle Wound Matrix for Post-Mohs Defects: A Randomized Controlled Multicenter First-In-Human Study. Dermatol[...]

A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023

Maverakis Ramirez N, Jaeger ZJ, Lee DJ. A Review of Randomized Controlled Trials for Vitiligo Therapies Published Between 2013 and 2023. Cureus. 2026 Jul 8;18(7):e112280.[...]

Multicytokine-based transcriptome-wide association study for 7 inflammatory skin disorders identifies candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]